Literature DB >> 11835380

Environmental enrichment slows disease progression in R6/2 Huntington's disease mice.

Emma Hockly1, Patricia M Cordery, Benjamin Woodman, Amarbirpal Mahal, Anton van Dellen, Colin Blakemore, Cathryn M Lewis, Anthony J Hannan, Gillian P Bates.   

Abstract

Huntington's disease is a genetic disorder that causes motor dysfunction, personality changes, dementia, and premature death. There is currently no effective therapy. Several transgenic models of Huntington's disease are available, the most widely used of which is the R6/2 mouse, because of its rapid disease progression. Environmental enrichment alters gene expression in the normal mouse brain, and modulates the course of several neurological disorders. Environmentally enriched mice may actually mimic human disease more accurately. We found that even limited environmental enrichment slows decline in RotaRod performance in R6/2 mice, despite rapid disease progression, whereas in normal littermates, maximal enrichment was required to induce a marked improvement in behavioral tests. Enrichment also delayed the loss of peristriatal cerebral volume in R6/2 brains. These results could provide the basis for a rational approach to ameliorate the effects of Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11835380     DOI: 10.1002/ana.10094

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  79 in total

Review 1.  Huntington's disease: a decade beyond gene discovery.

Authors:  Penelope Hogarth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

2.  Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.

Authors:  Miriam A Hickey; Chunni Zhu; Vera Medvedeva; Nicholas R Franich; Michael S Levine; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2011-10-20       Impact factor: 4.314

3.  FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease.

Authors:  Kunlin Jin; Michelle LaFevre-Bernt; Yunjuan Sun; Sylvia Chen; Juliette Gafni; Danielle Crippen; Anna Logvinova; Christopher A Ross; David A Greenberg; Lisa M Ellerby
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-02       Impact factor: 11.205

4.  Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.

Authors:  Danielle A Simmons; Rishi A Mehta; Julie C Lauterborn; Christine M Gall; Gary Lynch
Journal:  Neurobiol Dis       Date:  2010-10-23       Impact factor: 5.996

Review 5.  Stem Cells Transplantation and Huntington's Disease.

Authors:  Wooseok Im; Soon-Tae Lee; Kon Chu; Manho Kim; Jae-Kyu Roh
Journal:  Int J Stem Cells       Date:  2009-05       Impact factor: 2.500

6.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

7.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

Authors:  Elizabeth J Slow; Rona K Graham; Alexander P Osmand; Rebecca S Devon; Ge Lu; Yu Deng; Jacqui Pearson; Kuljeet Vaid; Nagat Bissada; Ronald Wetzel; Blair R Leavitt; Michael R Hayden
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

8.  Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease.

Authors:  Jennifer L Wacker; Shao-Yi Huang; Andrew D Steele; Rebecca Aron; Gregor P Lotz; QuangVu Nguyen; Flaviano Giorgini; Erik D Roberson; Susan Lindquist; Eliezer Masliah; Paul J Muchowski
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

9.  Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.

Authors:  Stephen C Fowler; Benjamin R Miller; Thomas W Gaither; Michael A Johnson; George V Rebec
Journal:  Behav Brain Res       Date:  2009-03-28       Impact factor: 3.332

10.  Mouse lipin-1 and lipin-2 cooperate to maintain glycerolipid homeostasis in liver and aging cerebellum.

Authors:  Jennifer R Dwyer; Jimmy Donkor; Peixiang Zhang; Lauren S Csaki; Laurent Vergnes; Jessica M Lee; Jay Dewald; David N Brindley; Elisa Atti; Sotirios Tetradis; Yuko Yoshinaga; Pieter J De Jong; Loren G Fong; Stephen G Young; Karen Reue
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.